TD Cowen analyst Tara Bancroft has maintained their neutral stance on FATE stock, giving a Hold rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tara Bancroft has given his Hold rating due to a combination of factors, balancing promising clinical momentum with remaining execution and regulatory risks. FT819’s progress in autoimmune diseases, including accelerated enrollment, outpatient feasibility, and supportive designations such as RMAT and CDRP, highlights a differentiated profile and underpins expectations for a potentially pivotal lupus nephritis study in the second half of 2026.
At the same time, the investment case remains highly dependent on successful advancement of early-stage programs and timely initiation of the registrational-intent trial, which introduces uncertainty around development, regulatory outcomes, and commercialization timelines. While the extended cash runway into 2028 and a catalyst-rich pipeline are positives, Tara Bancroft views the current share price as appropriately reflecting these opportunities and risks, supporting a neutral, Hold stance rather than a more aggressive rating.
According to TipRanks, Bancroft is a 5-star analyst with an average return of 31.0% and a 53.95% success rate. Bancroft covers the Healthcare sector, focusing on stocks such as Geron, Ocular Therapeutix, and Day One Biopharmaceuticals.